No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CLRB240816P2500
- 0.28
- +0.08+40.00%
15min DelayClose Jul 23 15:59 ET
0.40High0.20Low
0.20Open0.20Pre Close369 Volume581 Open Interest2.50Strike Price11.85KTurnover101.84%IV9.76%PremiumAug 16, 2024Expiry Date0.04Intrinsic Value100Multiplier24DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type-0.4676Delta0.6172Gamma8.95Leverage Ratio-0.0052Theta-0.0008Rho-4.18Eff Leverage0.0025Vega
Intraday
- 5D
- Daily
News
Cellectar Shares Fall as Updated Data For Investigational Radiotherapy Shows Drop in Major Response Rate
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Cellectar Falls After Updating Pivotal Data for Lead Asset
Top Premarket Decliners
Express News | Cellectar Biosciences Shares Are Trading Lower. The Company Announced Results From Its CLOVER WaM Pivotal Study Evaluating Iopofosine I 131
Comments
$Cellectar BioSciences(CLRB.US$ Look at that! Good PR price falls! But now its up almost 20% from the low it dropped to![]()
1
8
$Cellectar BioSciences(CLRB.US$ Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study With 78% of Major Response Patients Remaining Progression Free at 18 Months
7
Read more